Negotiating Drug Prices in the US—Lessons From Europe

Author:

Vokinger Kerstin N.1,Naci Huseyin2

Affiliation:

1. Institute of Law, University of Zurich, Zurich, Switzerland

2. Department of Health Policy, London School of Economics and Political Science, London, England

Abstract

This Viewpoint describes European drug price negotiation practices and compares them with practices in the US.

Publisher

American Medical Association (AMA)

Subject

General Earth and Planetary Sciences,General Environmental Science

Reference9 articles.

1. New reforms to prescription drug pricing in the US: opportunities and challenges.;Hwang;JAMA,2022

2. Analysis of launch and postapproval cancer drug pricing, clinical benefit, and policy implications in the US and Europe.;Vokinger;JAMA Oncol,2021

3. The use of ‘added benefit’ to determine the price of new anti-cancer drugs in France, 2004-2017.;Rodwin;Eur J Cancer,2021

4. The impact of price regulation on the availability of new drugs In Germany.;Stern;Health Aff (Millwood),2019

5. Congressional Budget Office. Prescription drugs: spending, use, and prices. Accessed October 30, 2022. https://www.cbo.gov/publication/57772

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3